Study register · detail
Unclear
GRADE
Very low
1 citations
Samplen = 10 Pat.
Durationprospective observation with…
Endpoint11-OH-THC blood concentration
Blindingn.a.
DesignKohortenstudie
Cannabinoidvollspektrum
Routeinhalativ
Key finding
Observational study without an intervention group; shows differences in cannabinoid metabolites between symptomatic and asymptomatic time points in adolescents with cannabinoid hyperemesis syndrome.
Summary
Pilot cohort of adolescent cannabis hyperemesis (n=10, screening n=869): 100% met CUDIT-R criteria for cannabis use disorder (n=9) or hazardous use (n=1), all reported withdrawal symptoms on attempted cessation. Significantly lower 11-OH-THC levels during the symptomatic episode [median 0,6 ng/mL, IQR: 0–2,6] vs. asymptomatic follow-up [median 4,2 ng/mL, IQR: 1,2–10,1].
P
PopulationAdolescent ED patients (14–21 years) with cyclic vomiting after chronic cannabis use (suspected cannabinoid hyperemesis syndrome), n=10
I
InterventionObservation of cannabis use patterns and blood profiles (cannabinoid metabolites, vitamins, minerals) in the symptomatic state and at an asymptomatic follow-up visit
O
OutcomeSignificantly lower 11-hydroxy-delta-9-THC levels in the symptomatic state (median 0,6 ng/mL) vs. asymptomatic follow-up visit (median 4,2 ng/mL); all participants had cannabis use disorder or hazardous cannabis use
Confidence in the evidence
Very low
The lowest GRADE level, the effect estimate remains uncertain.
Downgraded for
IndirectnessImprecision
Quality profile
Sample size
★★★★★
Blinding
—
Effect size
—
Citations / year
★★★★★
Authors
Share
Abstract
Objective: Adolescent use of cannabis in the United States is on the rise. Multiple toxicities and negative outcomes are possible with chronic or heavy cannabis use, including cannabinoid hyperemesis syndrome (CHS). This study analyzes a population of adolescent emergency department patients with cyclic vomiting onset after cannabis use, with a hypothesis that use patterns or biomarkers may offer insights into diagnostics, pathophysiology, or management of this disease.
Methods: This pilot prospective observational cohort study recruited pediatric emergency department patients aged 14 to 21 years with symptomatic cyclic vomiting onset after chronic cannabis use, and reassessed them at an asymptomatic follow-up visit. Cannabis use patterns were assessed with validated questionnaires, and blood profiles of cannabinoid metabolites and essential minerals and B vitamins were quantified and compared.
Results: We screened 869 adolescent ED patients and enrolled ten participants. All participants (n=10) had cannabis use disorder (n=9) or hazardous cannabis use (n=1) by the Cannabis Use Disorders Identification Test-Revised, and participants reported withdrawal symptoms when attempting to discontinue cannabis. There were significant differences in 11-hydroxy-delta-9-tetrahydrocannabinol between index [median 0.6 ng/mL (IQR: 0, 2.6)] and asymptomatic follow-up visits [median 4.2 ng/mL (IQR: 1.2, 10.1)]. Median vitamin and mineral concentrations were within reference ranges.
Conclusions: Symptomatic adolescent patients with suspected CHS had evidence of cannabis use disorder and had significantly lower blood concentrations of 11-hydroxy-delta-9-tetrahydrocannabinol when symptomatic. Further research is needed to better explore the pathophysiology and diagnostics in adolescent CHS, and exploration and treatment of cannabis use disorder should be considered in these patients.
The impediment to action advances action.